Take the Quiz
Guide · Updated October 16, 2026

BMI Eligibility for Semaglutide Weight Management

Wegovy label: BMI ≥30, or BMI ≥27 with weight-related comorbidity. 2024 expansion: adults with overweight/obesity + established CVD (SELECT enrolled adults with a BMI of 27 or more).

EducationalUpdated October 16, 2026
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated October 16, 2026

Overview

Wegovy label: BMI ≥30, or BMI ≥27 with weight-related comorbidity. 2024 expansion: adults with overweight/obesity + established CVD (SELECT enrolled adults with a BMI of 27 or more).

Related guides

Questions readers ask

What BMI do I need to qualify for Wegovy?

Wegovy’s label covers a BMI of 30 or higher, or 27 or higher with at least one weight-related condition such as hypertension, dyslipidemia, type 2 diabetes, sleep apnea or cardiovascular disease.

Do Ozempic and Rybelsus have BMI requirements?

No. Ozempic and Rybelsus are approved for type 2 diabetes regardless of BMI. BMI criteria apply to Wegovy’s chronic weight management indication, where the label threshold is a BMI of 30, or 27 with a weight-related condition.

Does Medicare cover GLP-1s based on BMI?

The Medicare GLP-1 Bridge, running July 1, 2026 to December 31, 2027, offers a $50 copay for eligible Part D members on Wegovy, Foundayo or Zepbound KwikPen, with prior authorization and BMI-based criteria.

Primary sources

  1. FDA: Concerns with unapproved GLP-1 drugs used for weight loss (current as of October 1, 2026)
  2. FDA: Policies for compounders as GLP-1 supply stabilizes (updated April 1, 2026)
  3. FDA: Compounding and the FDA — questions and answers
  4. FDA: Registered outsourcing facilities (503B)
  5. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021
  6. Wegovy (semaglutide) prescribing information, Novo Nordisk